Estudio aleatorizado, doble-ciego y controlado por placebo del efecto de un simbiótico sobre el tránsito intestinal en mujeres adultas sanas

Objetivo: Evaluar el tiempo de tránsito intestinal (TTI) antes y después de consumir yogur con Bifidobacterium BB12, Lactobacillus casei CRL 431 y fibra (simbiótico). Métodos: Estudio prospectivo, cruzado, aleatorizado y doble-ciego con 4 fases: preparación (tiempo 0); intervención (yogur o simbiótico; tiempo 1 y tiempo 3); sin intervención (tiempo 2). Evaluamos la frecuencia de defecación y el consumo de fibra. El TTI se estimo con rojo carmín. Resultados: La edad promedio fue 40,7 años (n = 102 mujeres sanas; 83 completaron el estudio). En mujeres con TTI inicial (TTII) > 48 h que consumieron el simbiótico, el TTII y el TTI final (TTIF) fue 86,9 ± 38,5 h y 51,2 ± 29,8 h (-40,9%), respectivamente, comparado con el de mujeres que consumieron el producto control (TTII, 80,8 ± 31,7 h; TTIF, 69,5 ± 31,5 h; -13,8%) (p = 0,001). En mujeres con constipación funcional que consumieron el producto control, el TTII fue 57,0 ± 30,0 h, valor que aumentó 2,8 h después de consumir el producto (TTIF, 59,8 ± 30,2 h; + 4,9%). El TTII en mujeres que consumieron el simbiótico fue 69,0 ± 49,6 h, registrándose una disminución de 27,5% 19 h después del consumo (TTIF, 50,0 ± 27,5 h; p = 0,023). La normalización de la flora láctica entérica fue significativamente mayor en mujeres que consumieron el simbiótico al inicio (p < 0,1). Conclusión: El TTI disminuyó significativamente después de consumir el simbiótico. Dicho efecto beneficioso fue más evidente en mujeres con TTII ≥ 48 h y constipación funcional.Objective: To evaluate oro-cecal intestinal transit time (ITT) before and after administration of a dairy product containing Bifidobacterium BB12, Lactobacillus casei CRL 431 and fiber in healthy women. Methods: A prospective, randomised, double-blind and cross-over study with a 4-phase design (run-in: time 0 [T0], two intervention periods: time 1 [T1] and time 3 [T3] and a wash-out: time 2, [T2]) was performed. Participants were asked about bowel movement and fiber consumption. ITT was assessed by the carmine red dye method. Results: Mean age was 40.7 years (n = 102 healthy women; 83 completed the study). In women with initial ITT (IITT) > 48 h consuming the synbiotic product, mean IITT and final ITT (FITT) was 86.9 ± 38.5 h and 51.2 ± 29.8 h (-40.9%), as compared to women consuming the control yoghurt (IITT, 80.8 ± 31.7 h; FITT, 69.5 ± 31.5 h; -13.8%) (p = 0.001). IITT in women with functional constipation consuming the control yoghurt was 57.0 ± 30.0 h; such figure increased 2.8 h after yoghurt consumption (FITT, 59.8 ± 3 0.2 h; +4.9%). Conversely, IITT in women who received the synbiotic yoghurt was 69.0 ± 49.6 h, with a -27.5% decrease 19 h later (FITT, 50.0 ± 27.5 h; p = 0.023). Enteric lactic flora stabilization was significantly higher in women who initially consumed the synbiotic product (p < 0.1). Conclusion: ITT decreased significantly after consumption of the synbiotic product. Such beneficial effect was more evident in women with IITT ≥ 48 h and with functional constipation.Fil: Malpeli, Agustina. Provincia de Buenos Aires. Ministerio de Salud. Comisión de Investigaciones Científicas. Hospital de Niños de La Plata. Instituto de Desarrollo e Investigaciones Pediátricas “Prof. Dr. Fernando E. Viteri”; ArgentinaFil: Gonzalez, Silvia Nelina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; Argentina. Universidad Nacional de Tucumán. Facultad de Bioquímica, Química y Farmacia; ArgentinaFil: Vicentin, Dimas. SanCor Cul. Departamento de Investigación, Innovación y Desarrollo; ArgentinaFil: Apas, Ana Lidia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; ArgentinaFil: González, Horacio F.. Provincia de Buenos Aires. Ministerio de Salud. Comisión de Investigaciones Científicas. Hospital de Niños de La Plata. Instituto de Desarrollo e Investigaciones Pediátricas “Prof. Dr. Fernando E. Viteri”; Argentin

Perfil de triacilgliceroles y porcentaje de ácido palmítico en la posición sn-2 en sustitutos de leche materna

The aim of this study was to analyze the percentage of palmitic acid at sn-2 position on triacylglycerols in infant formulas. We studied 6 infant formulas in the Argentinean market that are used as breast-milk substitutes during the first six months after delivery: 2 formulas with vegetable oils as basic source of lipids (F1, F2); 1 formula with milk fat and vegetable oils (F3); 1 formula with structured lipids and vegetable oils (F4); 2 formulas for pre-term infants, one with milk fat and other oils (F5), and the other with vegetable oils (F6). Results showed that F1, F2, F3 and F4 presented 14.6%, 14.8%, 48.1% and 44.5%, respectively, of palmitic acid at sn-2 position, whereas formulas F5 and F6 had 49.5% and 14.6%, respectively, of palmitic acid at sn-2 position. Milk-based infant formulas had the highest concentration of palmitic acid at sn-2 position.Instituto de Investigaciones Bioquímicas de La Plat

Perfil de triacilgliceroles y porcentaje de ácido palmítico en la posición sn-2 en sustitutos de leche materna

The aim of this study was to analyze the percentage of palmitic acid at sn-2 position on triacylglycerols in infant formulas. We studied 6 infant formulas in the Argentinean market that are used as breast-milk substitutes during the first six months after delivery: 2 formulas with vegetable oils as basic source of lipids (F1, F2); 1 formula with milk fat and vegetable oils (F3); 1 formula with structured lipids and vegetable oils (F4); 2 formulas for pre-term infants, one with milk fat and other oils (F5), and the other with vegetable oils (F6). Results showed that F1, F2, F3 and F4 presented 14.6%, 14.8%, 48.1% and 44.5%, respectively, of palmitic acid at sn-2 position, whereas formulas F5 and F6 had 49.5% and 14.6%, respectively, of palmitic acid at sn-2 position. Milk-based infant formulas had the highest concentration of palmitic acid at sn-2 position.Instituto de Investigaciones Bioquímicas de La Plat

Effect of daily consumption of Lactobacillus reuteri CRL 1098 on cholesterol reduction in hypercholesterolemic subjects

The effect of daily consumption of a yogurt containing Lactobacillus reuteri CRL 1098 on the lipid profile of hypercholesterolemic subjects was evaluated by performing a prospective, randomized, double-blind, cross-over placebo Controlled clinical study. Participants consumed daily a yogurt containing L. reuteri CRL 1098 or a placebo for four weeks, separated by a wash-out period. Total cholesterol, triacylglycerol, high-density (HDL) and low-density (LDL) lipoprotein levels were assessed at the beginning and at the end of each period. We found a statistically significant reduction of total (-7.86 g/dl) and LDL (-7.02 g/dl) cholesterol in absolute changes (before-after) as well as a decreasing trend in the group receiving the yogurt containing L. reuteri with respect to the placebo group, without detecting changes in HDL-cholesterol and triacylglycerol levels. Our results suggest that low amounts of yogurt (125 g/day) and low doses of the CRL 1098 strain (106 CFU) are sufficient to reduce total and LDL-cholesterol levels in hypercholesterolemic subjects.Fil: Malpeli, Agustina. Ministerio de Salud. Comisión de Investigaciones Científicas de la Provincia de Buenos Aires. Instituto de Desarrollo e Investigaciones Pediátricas “Prof. Dr. Fernando E. Viteri”. Hospital de Niños de La Plata; ArgentinaFil: Taranto, Maria Pia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; ArgentinaFil: Cravero, Ricardo C.. Sancor Cooperativas Unidas Limitada.; ArgentinaFil: Tavella, Marina. Ministerio de Salud. Comisión de Investigaciones Científicas de la Provincia de Buenos Aires. Instituto de Desarrollo e Investigaciones Pediátricas “Prof. Dr. Fernando E. Viteri”. Hospital de Niños de La Plata; ArgentinaFil: Fasano, Maria Victoria. Ministerio de Salud. Comisión de Investigaciones Científicas de la Provincia de Buenos Aires. Instituto de Desarrollo e Investigaciones Pediátricas “Prof. Dr. Fernando E. Viteri”. Hospital de Niños de La Plata; ArgentinaFil: Vicentin, Dimas. Sancor Cooperativas Unidas Limitada.; ArgentinaFil: Ferrari, Guillermina. Ministerio de Salud. Comisión de Investigaciones Científicas de la Provincia de Buenos Aires. Instituto de Desarrollo e Investigaciones Pediátricas “Prof. Dr. Fernando E. Viteri”. Hospital de Niños de La Plata; ArgentinaFil: Magrini, Graciano. Sancor Cooperativas Unidas Limitada.; ArgentinaFil: Hebert, Elvira Maria. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; ArgentinaFil: Font, Graciela Maria. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; ArgentinaFil: Varea, Ana María. Ministerio de Salud. Comisión de Investigaciones Científicas de la Provincia de Buenos Aires. Instituto de Desarrollo e Investigaciones Pediátricas “Prof. Dr. Fernando E. Viteri”. Hospital de Niños de La Plata; ArgentinaFil: Tavella, Julio Marcelo. Ministerio de Salud. Comisión de Investigaciones Científicas de la Provincia de Buenos Aires. Instituto de Desarrollo e Investigaciones Pediátricas “Prof. Dr. Fernando E. Viteri”. Hospital de Niños de La Plata; ArgentinaFil: González, Horacio F.. Ministerio de Salud. Comisión de Investigaciones Científicas de la Provincia de Buenos Aires. Instituto de Desarrollo e Investigaciones Pediátricas “Prof. Dr. Fernando E. Viteri”. Hospital de Niños de La Plata; Argentin

Effect of Daily Consumption of Lactobacillus reuteri CRL 1098 on Cholesterol Reduction in Hypercholesterolemic Subjects

The effect of daily consumption of a yogurt containing Lactobacillus reuteri CRL 1098 on the lipid profile of hypercholesterolemic subjects was evaluated by performing a prospective, randomized, double-blind, cross-over placebo controlled clinical study. Participants consumed daily a yogurt containing L. reuteri CRL 1098 or a placebo for four weeks, separated by a wash-out period. Total cholesterol, triacylglycerol, high-density (HDL) and low-density (LDL) lipoprotein levels were assessed at the beginning and at the end of each period. We found a statistically significant reduction of total (−7.86 g/dl) and LDL (−7.02 g/dl) cholesterol in absolute changes (before-after) as well as a decreasing trend in the group receiving the yogurt containing L. reuteri with respect to the placebo group, without detecting changes in HDL-cholesterol and triacylglycerol levels. Our results suggest that low amounts of yogurt (125 g/day) and low doses of the CRL 1098 strain (106 CFU) are sufficient to reduce total and LDL-cholesterol levels in hypercholesterolemic subjects.Facultad de Ciencias Médica

Effect of probiotic supplementation on immunoglobulins, isoagglutinins and antibody response in children of low socio-economic status

Background: Antigen exposure is one of the major exogenous factors modulating human immunocompetence acquisition. Decline in family size and improvements in public health and hygiene in developed countries, may deprive the immune system of appropriate antigen input by diminishing infectious stimuli. Probiotics are a large group of microorganisms defined by their beneficial effects on human health and with stimulating effects on different functions of the immune system. Aim of the study: We conducted a double-blind, placebo-controlled trial to determine if probiotics maintain their immune-stimulating effects in a population of 162 children with a high index of natural exposure to microorganisms. Children were to ingest for at least 4 months one of two products, low-fat milk fermented by Streptococcus thermophilus (control product) or low-fat milk fermented by S. thermophilus and Lactobacillus casei, with Lactobacillus acidophilus, oligofructose and inulin added after the fermentation process (test product). According to their age, children were vaccinated with DTP-Hib vaccine or a 23-valent anti-pneumococcal vaccine. Results: Final analysis of results was done in 70 children in each group, showing that the rate of immunoglobulin and isoagglutinin acquisition was similar in both groups. There was no difference between groups in antibody levels neither before nor after vaccination. Days of fever and number of episodes of infection were not statistically different in either group. Conclusions: Supplementation of standard fermented milk with additional probiotics was not of benefit. The high natural rate of early microbial exposure in infants and children from a population of low socio-economic status living in a "less hygienic environment" may account for the absence of an additional immune-stimulating effect by supplementary probiotics.Fil: Pérez, Néstor. Comisión de Investigaciones Científicas de la Provincia de Buenos Aires. Hospital de Niños de la Plata. Unidad de Inmunología; ArgentinaFil: Iannicelli, Juan C.. Comisión de Investigaciones Científicas de la Provincia de Buenos Aires. Hospital de Niños de la Plata. Unidad de Inmunología; ArgentinaFil: Girard-Bosch, Cecilia. Comisión de Investigaciones Científicas de la Provincia de Buenos Aires. Hospital de Niños de la Plata. Unidad de Inmunología; ArgentinaFil: Gonzalez, Silvia Nelina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; Argentina. Universidad Nacional de Tucumán. Facultad de Bioquímica, Química y Farmacia; ArgentinaFil: Varea, Ana. Comisión de Investigaciones Científicas de la Provincia de Buenos Aires. Hospital de Niños de la Plata. Unidad de Inmunología; ArgentinaFil: Disalvo, Liliana. Comisión de Investigaciones Científicas de la Provincia de Buenos Aires. Hospital de Niños de la Plata. Unidad de Inmunología; ArgentinaFil: Apezteguia, María. Comisión de Investigaciones Científicas de la Provincia de Buenos Aires. Hospital de Niños de la Plata. Unidad de Inmunología; ArgentinaFil: Pernas, Juan. Comisión de Investigaciones Científicas de la Provincia de Buenos Aires. Hospital de Niños de la Plata. Unidad de Inmunología; ArgentinaFil: Vicentin, Dimas. Sancor CUL. Departamento de Investigación, Innovación y Desarrollo; ArgentinaFil: Cravero, Ricardo. Sancor CUL. Departamento de Investigación, Innovación y Desarrollo; Argentin